| Authors: |
Powles T; Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London, UK. thomas.powles1@nhs.net., Sridhar SS; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Loriot Y; Gustave Roussy, INSERMU981, Université Paris-Saclay, Villejuif, France., Bellmunt J; Department of Medical Oncology, Beth Israel Deaconess Medical Center and IMIM-PSMAR Lab, Harvard Medical School, Boston, MA, USA., Mu XJ; Computational Biology, Oncology Research and Development, Pfizer, La Jolla, CA, USA., Ching KA; Computational Biology, Oncology Research and Development, Pfizer, La Jolla, CA, USA., Pu J; Statistics, Global Biometrics and Data Management, Pfizer, La Jolla, CA, USA., Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, Hematology/Oncology, Meyer Cancer Center, New York, NY, USA., Petrylak DP; Yale Cancer Center, New Haven, CT, USA., Tambaro R; Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS Fondazione Giovanni Pascale, Naples, Italy., Dourthe LM; Service d'Oncologie Médicale, Clinique St Anne, Strasbourg, France., Alvarez-Fernandez C; Department of Medical Oncology, Hospital Universitario Central de Asturias. Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain., Aarts M; Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands., di Pietro A; Pfizer Italia srl, Milano, Italy., Grivas P; Department of Medicine, Division of Medical Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA., Davis CB; Translational Oncology, Pfizer, La Jolla, CA, USA. craig.davis@pfizer.com. |
